Infants that are born before reaching full-term face a heightened risk of various health concerns that could pose long-term medical problems. One such condition is called bronchopulmonary dysplasia (BPD), or chronic lung disease, and according to the National Heart, Lung and Blood Institute, it primarily affects infants born 10 weeks or more before their due date and weigh under 2 pounds.
The institute notes that BPD is generally diagnosed if an infant requires oxygen therapy for an extended period after their birth. Many premature babies need this form of support due to impaired lung function, but these respiratory difficulties don’t always develop into BPD. In fact, a new study has revealed that a nutritional compound we’ve covered extensively on this blog could play a role in further diminishing this risk.
“Curcumin is known to have potent antioxidant, anti-inflammatory and anti-microbial properties, making it a promising therapy for premature infants who require oxygen therapy after birth,” said Dr. Virender Rehan of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in a press release distributed by ScienceDaily.
The press release notes that administering curcumin may protect premature infants from scarring and other damage that may be caused in part by the forced oxygen therapy they need to survive.
Curcumin has long been touted for its medicinal properties in certain parts of the world, and streams of new research have helped scientists better understand its benefits for memory support, cancer treatment and other applications. Click here to read more information about Nutrivene Longvida Curcumin Powder.